• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Radiotracer firms launch MoAb agents

Article

Two monoclonal-antibody-based radiopharmaceuticals that receivedFood and Drug Administration approval last year were launchedearly this month. Cytogen of Princeton, NJ, and marketing partnerC.R. Bard of Murray Hill, NJ, began selling their

Two monoclonal-antibody-based radiopharmaceuticals that receivedFood and Drug Administration approval last year were launchedearly this month. Cytogen of Princeton, NJ, and marketing partnerC.R. Bard of Murray Hill, NJ, began selling their ProstaScintagent for detecting prostate cancer (SCAN 11/6/96), while Du PontMerck Radiopharmaceuticals of North Billerica, MA, began sellingVerluma, a small-cell lung cancer imaging agent developed by NeoRxof Seattle (SCAN 9/25/96).

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.